{"id":"antiplatelet-therapy-ap","safety":{"commonSideEffects":[{"rate":"1–5","effect":"Bleeding"},{"rate":"0.5–2","effect":"Gastrointestinal bleeding"},{"rate":"5–15","effect":"Dyspepsia"},{"rate":null,"effect":"Bruising"}]},"_chembl":{"chemblId":"CHEMBL4302313","moleculeType":"Small molecule","molecularWeight":"307.43"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Antiplatelet agents work through various mechanisms—commonly by inhibiting cyclooxygenase (aspirin), blocking ADP receptors (clopidogrel, ticagrelor), or inhibiting phosphodiesterase—to reduce platelet clumping and thrombus formation. This prevents blood clots that can lead to myocardial infarction, stroke, and stent thrombosis in cardiovascular disease.","oneSentence":"Antiplatelet therapy inhibits platelet aggregation to prevent thrombotic events by blocking platelet activation pathways.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:02:01.845Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome"},{"name":"Secondary prevention of myocardial infarction"},{"name":"Ischemic stroke prevention"},{"name":"Peripheral arterial disease"}]},"trialDetails":[{"nctId":"NCT05611242","phase":"PHASE3","title":"Proximal Internal Carotid Artery Acute Stroke Secondary to Tandem or Local Occlusion Thrombectomy Trial","status":"RECRUITING","sponsor":"Mercy Health Ohio","startDate":"2024-05-08","conditions":"Acute Ischemic Stroke","enrollment":404},{"nctId":"NCT05627375","phase":"PHASE3","title":"Best Antithrombotic Therapy in Patients With Acute Venous ThromboEmbolism While Taking Antiplatelets","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2023-08-16","conditions":"Venous Thromboembolic Disease","enrollment":1400},{"nctId":"NCT05000060","phase":"PHASE3","title":"Restart TICrH AP Pilot Trial","status":"UNKNOWN","sponsor":"University of Texas at Austin","startDate":"2022-10-01","conditions":"Traumatic Intracranial Hemorrhage","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Antiplatelet therapy (AP)","genericName":"Antiplatelet therapy (AP)","companyName":"Centre Hospitalier Universitaire de Saint Etienne","companyId":"centre-hospitalier-universitaire-de-saint-etienne","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Antiplatelet therapy inhibits platelet aggregation to prevent thrombotic events by blocking platelet activation pathways. Used for Acute coronary syndrome, Secondary prevention of myocardial infarction, Ischemic stroke prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}